Cell Type-Selective, Potent Signaling Pathway Modulation Using A Guide-Effector Bispecific Design

Value Proposition

In targeting strategies for bispecific antibodies toxicity is a concern as both antibodies in some cases bind to signaling receptors critical for cell growth and survival. Approaches that allow modular development of bispecific antibodies with a goal of achieving maximum effect on a target cell (e.g. tumor) but no or minimum effect on normal cells would greatly improve the safety of new bispecific antibody therapeutics.

Technology Description

UCSF investigators have engineered bispecific antibodies and have demonstrated their anti-tumorigenic activities in vitro even in cases where the density ratio of the guide antigen to the effector antigen is high.

Patent Status